Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telomelysin - Oncolys Biopharma

Drug Profile

Telomelysin - Oncolys Biopharma

Alternative Names: OBP-301; Telomelysin

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncolys Biopharma
  • Developer Cornell University; Medigen Biotechnology Corporation; Okayama University; Oncolys BioPharma
  • Class Antineoplastics; Oncolytic viruses; Viral proteins
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastric cancer; Malignant melanoma; Oesophageal cancer
  • Phase I/II Head and neck cancer; Liver cancer; Non-small cell lung cancer
  • Phase I Solid tumours
  • Preclinical Neuroblastoma
  • No development reported Adenoid cystic carcinoma; Breast cancer; Mesothelioma; Osteosarcoma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 08 Apr 2019 Telomelysin licensed to Chugai Pharmaceutical for development and commercialisation in Japan and Taiwan
  • 29 Mar 2019 Adverse events data from a phase I trial in Solid tumours presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 29 Mar 2019 Pharmacodynamics from preclinical study in cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top